3 results
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMOCompleted
- to evaluate the FVIIa activity PK of 2 CSL689 dose levels in subjects with congenital FVII deficiency- to determine the PK characteristics of FVIIa activity of CSL689- to evaluate the safety and tolerability of intravenous administration of CSL689
Approved WMORecruiting
The goals of our study are: 1) to evaluate the performance of a single hs-troponin measurement using universal and sex-specific cut-off values; 2) to evaluate whether embedding hs-troponin in a clinical risk score (HEART, INTERCHEST, Marburg Heart…